# BAY 56-3722 in Treating Patients With Recurrent, Unresectable, or Metastatic Kidney Cancer

> **NCT00040989** · PHASE2 · WITHDRAWN · sponsor: **Jonsson Comprehensive Cancer Center**

## Conditions studied

- Stage IV Renal Cell Cancer
- Recurrent Renal Cell Cancer

## Interventions

- **DRUG:** BAY 56-3722
- **PROCEDURE:** enzyme inhibitor therapy

## Key facts

- **NCT ID:** NCT00040989
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2013-07-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00040989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00040989, "BAY 56-3722 in Treating Patients With Recurrent, Unresectable, or Metastatic Kidney Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00040989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*